DCTH

Business Context and Reporting Period

Company: Delcath Systems, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Stage: Development Stage Company
Overview: Delcath is developing a proprietary drug delivery system for high-dose chemotherapy to treat liver cancer (specifically malignant melanoma metastasized to the liver) using the agent Melphalan. The company has no commercial revenues and relies on equity financing and interest income. It is currently conducting Phase III clinical trials under an FDA Fast Track protocol.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Net Loss: The net loss for the six months ended June 30, 2007, increased by $703,271 compared to the same period in 2006. This was primarily driven by a five-year extension of the Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), which required a five-fold increase in annual payments.
• R&D Expense Growth: Research and development costs rose by approximately 48.6% ($681,533) year-over-year due to NCI payments and accelerated clinical development costs.
• G&A Expense Reduction: General and administrative expenses decreased by $79,233 year-over-year. This reduction was offset by share-based compensation for new Board members and cashless option exercises, which would have otherwise resulted in a larger decrease given lower legal fees.
• Declining Interest Income: Interest income dropped 33.2% year-over-year due to a reduced cash position compared to 2006.
• Liquidity Position: Cash and cash equivalents increased slightly from $6.29 million at year-end 2006 to $6.42 million at June 30, 2007, despite significant operating cash burn, aided by $1.34 million in proceeds from stock option exercises.

Guidance, Outlook, and Risks

• Capital Requirements: Management states the company has sufficient capital to operate through the end of 2007 but requires additional funding for R&D and clinical trials. A "shelf" registration statement (Form S-3) for up to $30 million in securities became effective on June 7, 2007, though no assurance of successful capital raising exists.
• Operational Focus: Over the next 12 months, the company expects to incur substantial expenses related to Phase III and Phase II clinical trials using Melphalan. Efforts are also underway to qualify additional sources for key device components to reduce manufacturing costs.
• Legal Proceedings: A libel lawsuit filed against a former director was dismissed on April 19, 2007, with the defendant granted recovery of costs. No other material legal proceedings are currently pending.
• Listing Risks: The company faces risks regarding NASDAQ Capital Market listing requirements, specifically regarding minimum bid price, market value of listed securities, and corporate governance (independent directors). The company recently regained compliance with governance requirements after a temporary lapse.
• Accounting Policies: The company adopted FASB Interpretation No. 48 regarding uncertainty in income taxes on January 1, 2007. It maintains a full valuation allowance against deferred tax assets.

Investor Verification Checklist

• Cash Runway: Verify if the $6.4 million cash balance is sufficient to fund the accelerated Phase III trials through the end of 2007 without immediate dilution.
• Capital Raise Status: Confirm whether any transactions have been consummated under the $30 million shelf registration filed in May 2007.
• NCI Agreement Terms: Review the specific financial obligations and milestones of the extended CRADA with the National Cancer Institute.
• NASDAQ Compliance: Monitor the stock price to ensure it remains above the $1.00 minimum bid price requirement to avoid delisting.
• Clinical Trial Progress: Track enrollment and data readouts for the Phase III melanoma trial to assess the timeline for potential FDA approval.